These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation. Marhäll A; Heidel F; Fischer T; Rönnstrand L Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308 [TBL] [Abstract][Full Text] [Related]
44. Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways. Yu M; Fang ZX; Wang WW; Zhang Y; Bu ZL; Liu M; Xiao XH; Zhang ZL; Zhang XM; Cao Y; Wang YY; Lei H; Xu HZ; Wu YZ; Liu W; Wu YL Acta Pharmacol Sin; 2021 Apr; 42(4):604-612. PubMed ID: 32694757 [TBL] [Abstract][Full Text] [Related]
45. Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia. Pillinger G; Abdul-Aziz A; Zaitseva L; Lawes M; MacEwan DJ; Bowles KM; Rushworth SA Sci Rep; 2015 Aug; 5():12949. PubMed ID: 26292723 [TBL] [Abstract][Full Text] [Related]
47. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Chen F; Ishikawa Y; Akashi A; Naoe T; Kiyoi H Oncotarget; 2016 Jul; 7(30):47018-47032. PubMed ID: 27331411 [TBL] [Abstract][Full Text] [Related]
48. Leukemogenic potency of the novel FLT3-N676K mutant. Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877 [TBL] [Abstract][Full Text] [Related]
49. Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors. Marensi V; Keeshan KR; MacEwan DJ Biochem Pharmacol; 2021 Jan; 183():114348. PubMed ID: 33242449 [TBL] [Abstract][Full Text] [Related]
50. SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations. Pandey R; Ramdas B; Wan C; Sandusky G; Mohseni M; Zhang C; Kapur R J Clin Invest; 2019 Dec; 129(12):5468-5473. PubMed ID: 31682240 [TBL] [Abstract][Full Text] [Related]
51. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354 [TBL] [Abstract][Full Text] [Related]
52. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives. Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823 [TBL] [Abstract][Full Text] [Related]
53. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Kiyoi H; Kawashima N; Ishikawa Y Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677 [TBL] [Abstract][Full Text] [Related]
54. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3. Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308 [TBL] [Abstract][Full Text] [Related]
55. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502 [TBL] [Abstract][Full Text] [Related]
56. Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia. Jiang K; Li X; Wang C; Hu X; Wang P; Tong L; Tu Y; Chen B; Jin T; Wang T; Wang H; Han Y; Gui R; Yang J; Liu T; Li J; Zhou Y Leukemia; 2023 Mar; 37(3):539-549. PubMed ID: 36526736 [TBL] [Abstract][Full Text] [Related]
57. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD). Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207 [TBL] [Abstract][Full Text] [Related]